Clinical Trials Browser

Phase 2 × INDUSTRY × abexinostat × Clear all

NCT03600441 2025-04-10

FORERUNNER

Phase 2 Active not recruiting

Lymphoma, Follicular, Neoplasms

NCT03936153 2025-04-10

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse